Gibtulio 10 Mg Tablet (Empagliflozin)

Description

Introduction

Gibtulio 10 Mg Tablet is identified as an oral tablet containing 10 mg of empagliflozin. Its stated indication is type 2 diabetes. Empagliflozin belongs to a group of medicines called sodium-glucose co-transporter 2 (SGLT2) inhibitors. The information below describes established effects and precautions for the active ingredient. A healthcare professional can provide guidance about the supplied product and its place in an individual treatment plan.

What Is It?

Gibtulio is a tablet formulation with a stated strength of 10 mg of empagliflozin per tablet. Empagliflozin helps manage blood glucose in type 2 diabetes. Diabetes care may also involve food choices, physical activity, glucose monitoring and other medicines. Empagliflozin controls blood glucose while it is being used; it does not cure diabetes. Kidney function, other medical conditions and existing medicines can affect treatment decisions.

How Does It Work?

The kidneys filter glucose from the blood and normally return much of it to the bloodstream. Empagliflozin blocks SGLT2, a protein involved in this reabsorption. More glucose then passes into urine, which can lower blood glucose. The process also increases the passage of water through the kidneys. Its glucose-lowering effect may be reduced when kidney function is impaired, so kidney assessment is relevant to treatment.

Common Uses

The stated indication for Gibtulio is type 2 diabetes. Empagliflozin may be part of a broader plan when blood glucose needs further management, either alone or with other diabetes medicines as determined by a clinician. The suitability of this product for a particular person or for any other condition requires product-specific professional guidance.

Available Strengths

This family is available in 10 mg, 25 mg.

Key Features

• The stated active ingredient is empagliflozin.
• The stated strength is 10 mg per oral tablet.
• Empagliflozin acts on SGLT2 in the kidneys to increase glucose excretion in urine.
• The identified indication for this product is type 2 diabetes.
• Kidney function, hydration and other glucose-lowering medicines are relevant to clinical review.

Benefits

• Empagliflozin has been shown to lower blood glucose in people with type 2 diabetes.
• Its action in the kidneys differs from that of medicines that stimulate insulin release.
• Empagliflozin can be used with certain other diabetes medicines when a clinician considers the combination appropriate.
• Blood glucose measurements can help a healthcare professional assess the response to treatment. The degree of benefit varies between people.

Possible Side Effects

• Passing urine more often, including at night, and increased thirst can occur.
• Genital yeast infections may cause itching, redness or discharge. Urinary tract infections may cause burning or frequent urination, pain or fever.
• Fluid loss can cause dehydration, dizziness or low blood pressure, particularly during illness or when other medicines also increase fluid loss.
• Low blood glucose is more likely when empagliflozin is used with insulin or a sulfonylurea.
• Serious problems can include ketoacidosis, severe urinary infection, a serious infection around the genitals or perineum, and allergic reactions. Vomiting, abdominal pain, difficulty breathing, unusual drowsiness, fever with genital pain or swelling, or facial swelling require urgent medical assessment.

Precautions

• Empagliflozin is not a treatment for type 1 diabetes or diabetic ketoacidosis.
• Kidney function affects the glucose-lowering response and should be considered by a healthcare professional.
• Vomiting, diarrhoea, reduced food or fluid intake, acute illness and surgery can alter treatment risks.
• A history of urinary or genital infections, low blood pressure, pancreatic disease or ketoacidosis should be discussed with a healthcare professional.
• Pregnancy, plans for pregnancy and breastfeeding require professional advice before treatment decisions are made.

Additional Precautions

• Ketoacidosis may occur without markedly raised blood glucose. Nausea, vomiting, abdominal pain, excessive thirst, difficulty breathing or unusual tiredness need prompt assessment.
• A clinician may advise temporary changes to treatment during major surgery or serious illness and decide when it can resume.
• Urine may test positive for glucose because of empagliflozin’s action. Tell the clinician or laboratory about its use when tests are arranged.
• New foot sores, pain or signs of infection warrant medical attention, especially when circulation or nerve problems are present.
• Check the supplied pack and leaflet for product-specific warnings, inactive ingredients and storage directions.

Storage Instructions

• Keep tablets in their original packaging and out of sight and reach of children.
• Keep them away from excess heat and moisture.
• Follow the storage directions and expiry date printed on the supplied pack. Ask a pharmacist if these directions are unclear.
• Ask a pharmacist about appropriate disposal of expired or unwanted tablets.

How to Take

• Gibtulio is an oral tablet. Follow the directions provided by the prescribing healthcare professional and with the supplied product.
• Empagliflozin tablets can generally be taken with or without food; check the directions for the supplied pack.
• A healthcare professional determines the dose and reviews treatment in light of kidney function, blood glucose and other medicines.
• Ask a pharmacist or prescriber for guidance about a missed tablet, an illness or an upcoming procedure. Dose changes need professional advice.

Drug Interactions

• Insulin and sulfonylureas can increase the risk of low blood glucose when used with empagliflozin.
• Diuretics, including some medicines used for blood pressure or fluid retention, may add to fluid loss and increase the risk of dehydration or low blood pressure.
• Other medicines that affect blood glucose, blood pressure or kidney function may need review and monitoring.
• A healthcare professional should have a complete list of prescription medicines, non-prescription products and supplements when assessing possible interactions.

Why Choose This Product?

• It provides the stated active ingredient, empagliflozin, in a 10 mg oral tablet.
• Empagliflozin has an established SGLT2 mechanism and evidence for lowering blood glucose in type 2 diabetes.
• Whether this product fits a treatment plan depends on clinical needs, tolerability and the details of the supplied pack.

Frequently Asked Questions (FAQs)

What is the active ingredient?

The stated active ingredient is empagliflozin. The stated strength is 10 mg per tablet.

What condition is Gibtulio identified for?

The identified indication is type 2 diabetes. A healthcare professional can clarify the intended use of the supplied product.

How does empagliflozin lower blood glucose?

It blocks SGLT2 in the kidneys, allowing more glucose to leave the body in urine.

Is empagliflozin used to treat type 1 diabetes?

No. Empagliflozin is not used to treat type 1 diabetes.

Can it be used with other diabetes medicines?

It may be prescribed with other medicines. Combinations require clinical review, particularly with insulin or a sulfonylurea because of the risk of low blood glucose.

What symptoms need urgent attention?

Vomiting, abdominal pain, difficulty breathing, unusual drowsiness, severe genital pain or swelling, and signs of a serious allergic reaction need urgent medical assessment.

Can kidney problems affect treatment?

Yes. Kidney function can affect empagliflozin’s glucose-lowering effect and treatment decisions.

Does a positive urine glucose test mean treatment is failing?

No. Empagliflozin increases glucose in urine as part of its action. A healthcare professional can interpret test results in context.

How should the tablets be stored?

Keep them in the original packaging, away from excess heat and moisture, and follow the directions on the supplied pack.

Related Products

• Gibtulio 10 Mg Tablet (Empagliflozin)
• Gibtulio 25 Mg Tablet (Empagliflozin)
• Glimepiride 1 mg Australia
• Acarbose 25 mg Australia
• Miglitol 50 mg Australia
• Voglibose 0.2 mg Australia